This document presents the core protocol for ECDC studies of CVE and IVE against symptomatic laboratory-confirmed influenza or SARS-CoV-2 infection, respectively, at primary care level.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 21-27 May 2023 and includes updates on COVID-19, influenza, Marburg virus disease, poliomyelitis, extensively drug-resistant Pseudomonas aeruginosa, and suspected fungal meningitis.
Following a peak at week 51/2022, influenza activity had been decreasing across the Region until week 4/2023, before rising again to fluctuate around 25% positivity between weeks 6 and 11/2023 and decreasing below 10% positivity in week 16/2023.
Following a peak at week 51/2022, influenza activity had been decreasing across the Region until week 4/2023 when it reached 21% positivity, before rising again to fluctuate around 25% positivity between weeks 6 and 11/2023 and is coming to an end with positivity falling below the 10% seasonal threshold in week 16/2023 (9%).
Following a peak at week 51/2022, influenza activity had been decreasing across the Region until week 4/2023, before rising again to fluctuate around 25% positivity between weeks 6 and 11/2023 and decreasing below 10% positivity in week 16/2023.
